Page 1224 - Hematology_ Basic Principles and Practice ( PDFDrive )

1070 Part VII Hematologic Malignancies

REFERENCES 15. Baccarani M, Deininger MW, Rosti G, et al: (2013) European Leu-
kemiaNet recommendations for the management of chronic myeloid
1. Perrotti D, Jamieson C, Goldman J, et al: Chronic myeloid leukemia: leukemia. Blood 122(6):872–884, 2013.
Mechanisms of blastic transformation. J Clin Invest 120:2254, 2010. 16. Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for
2. Goldman JM, Melo JV: Chronic myeloid leukemia—Advances in achieving molecular responses in patients with chronic myeloid leukemia
biology and new approaches to treatment. N Engl J Med 349:1451, 2003. who achieve complete cytogenetic responses on imatinib. J Clin Oncol
3. Branford S, Fletcher L, Cross NC, et al: Desirable performance charac- 28:2381, 2011.
teristics for BCR-ABL measurement on an international reporting scale 17. Deininger MW, O’Brien SG, Ford JM, et al: Practical management of
to allow consistent interpretation of individual patient response and patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol
comparison of response rates between clinical trials. Blood 112:3330, 21:1637, 2003.
2008. 18. Soverini S, Hochhaus A, Nicolini FE, et al: BCR-ABL kinase domain
4. Corm S, Roche L, Micol JB, et al: Changes in the dynamics of the mutation analysis in chronic myeloid leukemia patients treated with
excess mortality rate in chronic phase-chronic myeloid leukemia over tyrosine kinase inhibitors: Recommendations from an expert panel on
1990–2007: A population study. Blood 118:4331, 2011. behalf of European LeukemiaNet. Blood 118:1208, 2011.
5. Gambacorti-Passerini C, Antolini L, Mahon FX, et al: Multicenter inde- 19. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in
pendent assessment of outcomes in chronic myeloid leukemia patients newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med
treated with imatinib. J Natl Cancer Inst 103:553, 2011. 362:2260, 2010.
6. Druker B, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor 20. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for
of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251,
Med 2:561, 1996. 2010.
7. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific 21. Berman E: Where exactly does ponatinib fit in chronic myelogenous
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. leukemia? J Natl Compr Canc Netw 12:1615–1620, 2014.
N Engl J Med 344:1031, 2001. 22. Alvandi F, Kwitkowski VE, Ko CW, et al: U.S. Food and Drug Admin-
8. O’Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with istration approval summary: omacetaxine mepesuccinate as treatment for
interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. Oncologist 19:94–99, 2014.
chronic myeloid leukemia. N Engl J Med 348:994, 2003. 23. Chu S, McDonald T, Lin A, et al: Persistence of leukemia stem cells
9. Hochhaus A, O’Brien SG, Guilhot F, et al: Six-year follow-up of patients in chronic myelogenous leukemia patients in prolonged remission with
receiving imatinib for the first-line treatment of chronic myeloid leuke- imatinib treatment. Blood 118:5565, 2011.
mia. Leukemia 23:1054, 2009. 24. Mahon FX, Rea D, Guilhot J, et al: Discontinuation of imatinib in
10. Cortes JE, Baccarani M, Guilhot F, et al: Phase III, randomized, open- patients with chronic myeloid leukaemia who have maintained complete
label study of daily imatinib mesylate 400 mg versus 800 mg in patients molecular remission for at least 2 years: The prospective, multicentre
with newly diagnosed, previously untreated chronic myeloid leukemia Stop Imatinib (STIM) trial. Lancet Oncol 11:1029, 2010.
in chronic phase using molecular end points: Tyrosine kinase inhibitor 25. Palani R, Milojkovic D, Apperley JF: Managing pregnancy in
optimization and selectivity study. J Clin Oncol 28:424, 2010. chronic myeloid leukaemia. Ann Hematol 94(Suppl 2):S167–S176,
11. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly 2015.
diagnosed patients with chronic myeloid leukemia: Incidence of sus- 26. Khoury HJ, Kukreja M, Goldman JM, et al: Prognostic factors for
tained responses in an intention-to-treat analysis. J Clin Oncol 26:3358, outcomes in allogeneic transplantation for CML in the imatinib era: A
2008. CIBMTR analysis. Bone Marrow Transplant 2011.
12. Efficace F, Baccarani M, Breccia M, et al: Health-related quality of life 27. Basak G, Torosian T, Snarski E, et al: Hematopoietic stem cell trans-
in chronic myeloid leukemia patients receiving long-term therapy with plantation for T315I-mutated chronic myelogenous leukemia. Ann
imatinib compared with the general population. Blood 118:4554, 2011. Transplant 15:68, 2010.
13. Hughes TP, Hochhaus A, Branford S, et al: Long-term prognostic signifi- 28. Kebriaei P, Detry MA, Giralt S, et al: Long-term follow-up of allogeneic
cance of early molecular response to imatinib in newly diagnosed chronic hematopoietic stem-cell transplantation with reduced-intensity condi-
myeloid leukemia: An analysis from the International Randomized Study tioning for patients with chronic myeloid leukemia. Blood 110:3456,
of Interferon and STI571 (IRIS). Blood 116:3758, 2010. 2007.
14. Marin D, Ibrahim AR, Lucas C, et al: Assessment of BCR-ABL1 Tran- 29. Jabbour E, Cortes J, Santos FP, et al: Results of allogeneic hematopoietic
script levels at 3 months is the only requirement for predicting outcome stem cell transplantation for chronic myelogenous leukemia patients
for patients with chronic myeloid leukemia treated with tyrosine kinase who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase
inhibitors. J Clin Oncol 30:232, 2012. domain mutations. Blood 117:3641, 2011.